Valbiotis Outlines 2030 Strategic and Financial Targets

Valbiotis, a French laboratory specializing in dietary supplements, has unveiled its strategic goals for 2030. The company plans to release three products for managing cardiometabolic disorders in France by mid-year, expecting significant sales from 2025. Valbiotis aims for a turnover of over €25 million in 2027, with a positive EBITDA in France. By 2030, they target over €100 million in turnover, with 30% from international sales and an EBITDA margin of 25-30%.

CEO Sébastien Peltier emphasizes the company's readiness to focus on marketing. Valbiotis has demonstrated product efficacy through rigorous clinical studies, including their first product, Valbiotis®PRO Cholesterol. Two more launches are scheduled for mid-2025, anticipated to boost sales. The firm aims to enhance its presence both domestically and internationally, focusing on markets in the USA, Europe, and Asia through strategic partnerships.